Rossari Biotech Limited (ROSSARI)

Chemicals · Chemicals & Petrochemicals · NSE · Updated 15 July 2026

₹535.75 ↓ 27.85% (1Y)

🎯 Key Takeaways

Rossari Biotech is in a mature phase with signs of stabilization after a period of growth, currently navigating margin pressure and flat-to-slightly declining revenue trends. The company maintains consistent profitability but faces headwinds reflected in its 1Y return of -27.
Revenue grew 2.9% QoQ to ₹513 in Q3FY25.
⚠️ Margin pressure persists despite revenue growth, with OPM declining slightly over the last two years, indicating potential pricing or input cost chall

Market Cap

₹2,806

P/E Ratio

20.6

Div Yield

0.00%

Promoter

0.0%

✨ Ask AI About ROSSARI 📊 Interactive Charts

📖 The Story

Rossari Biotech is in a mature phase with signs of stabilization after a period of growth, currently navigating margin pressure and flat-to-slightly declining revenue trends. The company maintains consistent profitability but faces headwinds reflected in its 1Y return of -27.85%. Management is focused on operational continuity and shareholder engagement through structured investor events and governance updates.

📰 What's Happening

In the past quarter, Rossari Biotech scheduled its Q1 FY27 earnings call for July 20, 2026, following results declaration on July 18, 2026, to discuss performance and field analyst queries. Concurrently, it conducted its 17th Annual General Meeting on July 20, 2026 via video conference, with a record date of July 10, 2026 for dividend eligibility and e-voting participation until July 13, 2026. The Integrated Annual Report for FY2025-26 was made accessible online, and dividend payout was to be completed within 10 working days post-AGM. Additionally, trading restrictions were imposed on designated persons until 48 hours after the unaudited Q1 FY27 results announcement on June 30, 2026.

Source: Stock Announcements

📊 Quarterly Results (₹ Cr)

Metric	Q4FY23	Q1FY24	Q2FY24	Q3FY24	Q4FY24	Q1FY25	Q2FY25	Q3FY25
Revenue	406	411	483	464	473	490	498	513
Operating Profit	57	60	65	67	64	66	67	65
OPM %	13.4%	14.1%	13.2%	13.7%	13.4%	13.3%	13.2%	12.6%
Net Profit	29	29	33	34	34	35	35	32
EPS	₹5.25	₹5.30	₹5.97	₹6.23	₹6.18	₹6.32	₹6.39	₹5.73

The company's quarterly revenue has shown a gradual upward trend from ₹406 crore in Q4FY23 to ₹513 crore in Q3FY25, indicating modest growth momentum. However, operating profit and margins have plateaued, with OPM declining slightly from 13.4% in Q4FY23 to 12.6% in Q3FY25, suggesting margin compression despite revenue gains. Net profit and EPS have remained relatively stable in the ₹32–35 crore and ₹5.7–6.4 range over the last four quarters, reflecting operational resilience but limited expansion. This stability appears to be the result of sustained cost management rather than top-line acceleration.

🔮 Management Outlook & What's Next

Management has not provided explicit forward guidance on revenue or margin expectations in the available filings. However, the scheduled Q1 FY27 earnings call on July 20, 2026, is positioned as a key forum for discussing performance and addressing investor inquiries, implying anticipation of continued operational performance in line with recent trends. The timing of investor events and AGM suggests an active engagement strategy, though no strategic targets or outlook statements were disclosed in the reviewed announcements.

Extracted from official company announcements. Not StockFin.ai's opinion.

⚖️ Peer Comparison — Chemicals & Petrochemicals

Company	MCap (₹ Cr)	P/E	ROCE	ROE	D/E
Solar Industries India Limited	1.57 L Cr	132.3	—	—	—
Pidilite Industries Limited	1.49 L Cr	75.7	—	—	—
SRF Limited	79,723	69.5	—	—	—
Linde India Limited	62,701	141.9	—	—	—
Gujarat Fluorochemicals Limited	40,793	89.6	—	—	—
Navin Fluorine International Limited	35,894	131.5	—	—	—
Himadri Speciality Chemical Limited	30,071	56.6	—	—	—
Deepak Nitrite Limited	24,911	33.3	—	—	—
Atul Limited	20,904	48.8	—	—	—
Tata Chemicals Limited	19,079	-47.1	—	—	—

🔗 Peer Stock Analyses

SOLARINDS PIDILITIND SRF LINDEINDIA FLUOROCHEM

⚠️ Risk Factors

1. Margin pressure persists despite revenue growth, with OPM declining slightly over the last two years, indicating potential pricing or input cost challenges not fully offset by scale. 2. No clear growth catalyst or expansion initiative has been announced in the recent filings, raising concerns about top-line stagnation. 3. Management has not provided forward-looking guidance, creating uncertainty around future performance expectations. 4. The company operates in a capital-intensive chemical sector where working capital efficiency and raw material volatility could impact profitability if not managed proactively.

📋 Recent Filings

🧠 Analyst's Read

Rossari Biotech appears to be in a stabilization phase with steady but unspectacular financial performance. Investors should monitor the upcoming Q1 FY27 earnings call for early signals on demand trends, margin trajectory, and potential strategic updates. The company’s ability to maintain profitability amid flat growth will be critical, as will any shift in capital allocation strategy or visibility into new growth verticals.

Based on filing content and financial data. Not a recommendation.

Read the full analysis

Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.

2 free AI queries per day.

✨ Deep Dive with AI on ROSSARI

Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-07-15.

📡 Get AI alerts when ROSSARI files new disclosures

Track ROSSARI filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track ROSSARI — Free

Free account · 2 AI queries/day